NCT05523817 Targeting Specific Brain Networks to Treat Specific Symptoms in Depression
| NCT ID | NCT05523817 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Massachusetts General Hospital |
| Condition | Major Depressive Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2024-03-12 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2024-03-12 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Repetitive transcranial magnetic stimulation (rTMS) is a way of non-invasively stimulating specific brain networks and is an established treatment for Major Depressive Disorder (MDD). This proposal will reveal network mechanisms of the therapeutic effects of rTMS by investigating how stimulating each network specifically changes network connectivity and behavior. This will be done in a highly individualized manner in depressed and healthy patients, leading to more effective and more individualized treatments for depression.
Eligibility Criteria
Inclusion Criteria for healthy participants: * 18-65 years of age * Capacity to provide informed consent form to participate in the study Inclusion Criteria for participants with Major Depressive Disorder (MDD): * 18-65 years of age * Capacity to provide informed consent form to participate in the study * Currently in a major depressive episode. Comorbid anxiety disorders and personality disorders will be allowed provided that MDD is the primary diagnosis. Exclusion Criteria for all participants: * Meeting criteria, in the past or currently, for bipolar affective disorder, hypomania or mania. * Meeting criteria, in the past or currently, for a primary psychotic disorder (e.g., schizophrenia). * Neurological conditions with known structural brain lesions, e.g., intracranial masses, multiple sclerosis. * Any personal history of seizures or a family history of epilepsy in a first-degree relative. * Metal in the body that is ferromagnetic or metallic injury to the eyes. * Implanted pacemakers, medication pumps, vagal stimulators, deep brain stimulators, or ventriculoperitoneal shunts, etc. * Substance abuse or dependence that is current and active within the last six months, as indicated by self-report (e.g., heroin, cocaine, methamphetamines). * Inability to meet the safety criteria for MRI scanning for any other reason. * Severe or unstable medical illness. * Currently pregnant, as assessed with urine pregnancy test in women of childbearing age.
Frequently Asked Questions
Who can join the NCT05523817 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Major Depressive Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05523817 currently recruiting?
Yes, NCT05523817 is actively recruiting participants. Visit ClinicalTrials.gov or contact Massachusetts General Hospital to inquire about joining.
Where is the NCT05523817 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT05523817 clinical trial?
NCT05523817 is sponsored by Massachusetts General Hospital. The trial plans to enroll 80 participants.